KRAS and acute lymphoblastic leukemia: Previously described neo-antigens formed by RAS-isoform mutations and the BCR-ABL1 fusion protein were also predicted in this study, and the KRAS G13D mutation was found to generate a stable neo-antigen:HLA complex in 12% and 20% of hyperdiploid and hypodiploid B-ALL patients, respectively.